Hypothalamic AAV-BDNF gene therapy improves metabolic function and behavior in the Magel2-null mouse model of Prader-Willi syndrome

Individuals with Prader-Willi syndrome (PWS) display developmental delays, cognitive impairment, excessive hunger, obesity, and various behavioral abnormalities. Current PWS treatments are limited to strict supervision of food intake and growth hormone therapy, highlighting the need for new therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Queen, Nicholas J., Zou, Xunchang, Anderson, Jacqueline M., Huang, Wei, Appana, Bhavya, Komatineni, Suraj, Wevrick, Rachel, Cao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573893/
https://www.ncbi.nlm.nih.gov/pubmed/36284766
http://dx.doi.org/10.1016/j.omtm.2022.09.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573893/
https://www.ncbi.nlm.nih.gov/pubmed/36284766
http://dx.doi.org/10.1016/j.omtm.2022.09.012

Ejemplares similares